# US 12,599,619 B2 · Method of treating blepharitis or conjunctivitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,619 B2
- Document ID: US12599619B2
- Status: Granted
- Kind: B2
- Application number: 17/803,311
- Filed: 2022-05-03
- Published: 2022-08-25
- Granted: 2026-04-14
- Earliest claimed: 2018-11-30
- Assignees: IVIEW Therapeutics, Inc.
- Applicants: Iview Therapeutics, Inc.
- Inventors: Edward T. Wei
- Web page: https://patentgrep.com/patent/US12599619B2

## CPC

- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/66: Phosphorus compounds
- A61K 47/02: Inorganic compounds
- A61P 17/04: Antipruritics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.

## Claims

### Claim 1

A method for the treatment of blepharitis or conjunctivitis in a subject in need thereof, comprising:
topically applying a liquid or semi-liquid composition to an ocular surface or an area of periorbital facial skin of the subject, the composition comprising a therapeutically effective amount of one or more compounds having Formula 1 dissolved therein
wherein R is n-heptyl, n-octyl or n-nonyl; and
wherein the conjunctivitis is caused by administration of dupilumab to a subject with eczema.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is topically applied to the subject's ocular surface.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is topically applied to an area of periorbital facial skin of the subject, wherein the area of periorbital facial skin comprises an eyelid.

### Claim 4 (depends on 1)

The method of claim 1, wherein the liquid or semi-liquid composition comprises from about 0.05 to 2% by weight of the one or more compounds of Formula 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises the one or more compounds of Formula 1 at a concentration of 1-20 mg/ml.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is a liquid composition comprising the one or more compounds of Formula 1 at a concentration of 1-5 mg/mL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for blepharitis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has eczema and is in need of treatment for conjunctivitis caused by administration of dupilumab.